<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DRISDOL- ergocalciferol capsule, liquid filled </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>DRISDOL® <br>ERGOCALCIFEROL, USP <br>50,000 IU Capsule</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DRISDOL, brand of ergocalciferol capsules, USP, is a synthetic calcium regulator for oral administration.</p>
<p>Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils.  It is affected by air and by light.  Ergosterol or provitamin D2 is found in plants and yeast and has no antirachitic activity.</p>
<p>There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity.</p>
<p>One USP unit of vitamin D<span class="Sub">2</span> is equivalent to one International Unit (IU), and 1 mcg of vitamin D<span class="Sub">2</span> is equal to 40 IU.</p>
<p>Each capsule contains 1.25 mg (50,000 International Units vitamin D) of ergocalciferol, USP, in an edible vegetable oil.</p>
<p>Ergocalciferol, also called vitamin D<span class="Sub">2</span>, is 9,10-secoergosta-5,7,10(19),22-tetraen-3-ol,(3ß,5Z,7E,22<span class="Italics">E</span>)-; (C<span class="Sub">28</span>H<span class="Sub">44</span>O) with a molecular weight of 396.65, and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d501431-82d3-4f8e-94c4-5eabcefc00ad&amp;name=drisdol-01.jpg"></div>
<p><span class="Bold Italics">Inactive Ingredients:</span>FD&amp;C Blue #1, FD&amp;C Yellow #5, Gelatin, Glycerin, Soybean Oil.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization.  Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.</p>
<p>There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys.  Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DRISDOL is indicated for use in the treatment of <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span>, refractory <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">rickets</span>, also known as vitamin D resistant <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">rickets</span>, and familial <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">DRISDOL is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, abnormal sensitivity to the toxic effects of vitamin D, and <span class="product-label-link" type="condition" conceptid="435522" conceptname="Hypervitaminosis D">hypervitaminosis D</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to vitamin D may be one etiologic factor in infants with idiopathic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.  In these cases vitamin D must be strictly restricted.</p>
<p>Keep out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement.  Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">RICKETS</span> THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span>, intravenous calcium, parathyroid hormone, and/or dihydrotachysterol may be required.</p>
<p>Maintenance of a normal serum phosphorus level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> as frequently seen in <span class="product-label-link" type="condition" conceptid="197921" conceptname="Renal osteodystrophy">renal osteodystrophy</span> is essential to prevent metastatic calcification.</p>
<p>Adequate dietary calcium is necessary for clinical response to vitamin D therapy.</p>
<p>This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals.  Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>Protect from light.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.</p>
<p>Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with DRISDOL may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term animal studies have been performed to evaluate the drug's potential in these areas.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.4"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have shown fetal abnormalities in several species associated with <span class="product-label-link" type="condition" conceptid="435522" conceptname="Hypervitaminosis D">hypervitaminosis D</span>. These are similar to the <span class="product-label-link" type="condition" conceptid="4147787" conceptname="Supravalvar aortic stenosis">supravalvular aortic stenosis</span> syndrome described in infants by Black in England (1963).  This syndrome was characterized by <span class="product-label-link" type="condition" conceptid="4147787" conceptname="Supravalvar aortic stenosis">supravalvular aortic stenosis</span>, elfin facies, and <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>.  For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved.  The safety in excess of 400 IU of vitamin D daily during pregnancy has not been established.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caution should be exercised when DRISDOL is administered to a nursing woman.  In a mother given large doses of vitamin D, 25-hydroxycholecalciferol appeared in the milk and caused <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in her child. Monitoring of the infant's serum calcium concentration is required in that case (Goldberg, 1972).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Pediatric doses must be individualized (see <a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DRISDOL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger, individuals.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435522" conceptname="Hypervitaminosis D">Hypervitaminosis D</span> is characterized by effects on the following organ system:</p>
<p><span class="Bold">Renal:</span>Impairment of renal function with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, reversible <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>, generalized <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span>, or irreversible <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> which may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="Bold">CNS:</span><span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">Mental retardation</span>.</p>
<p><span class="Bold">Soft Tissues:</span>Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs.</p>
<p><span class="Bold">Skeletal:</span>Bone demineralization (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) in adults occurs concomitantly.</p>
<p>Decline in the average rate of linear growth and increased mineralization of bones in infants and children (<span class="product-label-link" type="condition" conceptid="25780" conceptname="Pituitary dwarfism">dwarfism</span>) vague <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Bold">Gastrointestinal:</span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold">Metabolic:</span>Mild <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="Bold">The effects of administered vitamin D can persist for two or more months after cessation of treatment.</span></p>
<p><span class="product-label-link" type="condition" conceptid="435522" conceptname="Hypervitaminosis D">Hypervitaminosis D</span> is characterized by:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, vague <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span> and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and mild <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</li>
<li>Impairment of renal function with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, reversible <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>, generalized <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span>, or irreversible <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> which may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) in adults occurs concomitantly.</li>
<li>Decline in the average rate of linear growth and increased mineralization of bones in infants and children (<span class="product-label-link" type="condition" conceptid="25780" conceptname="Pituitary dwarfism">dwarfism</span>).</li>
</ol>
<p>The treatment of <span class="product-label-link" type="condition" conceptid="435522" conceptname="Hypervitaminosis D">hypervitaminosis D</span> with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment.  Hypercalcemic crisis with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens.  With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> via renal or cardiovascular failure have been reported.</p>
<p>The LD<span class="Sub">50</span> in animals is unknown.  The toxic oral dose of ergocalciferol in the dog is 4 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage_administration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW.</p>
<p><span class="Bold">Vitamin D Resistant <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">Rickets</span>:</span>12,000 to 500,000 IU units daily.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">Hypoparathyroidism</span>:</span>50,000 to 200,000 IU units daily concomitantly with calcium lactate 4 g, six times per day.</p>
<p>DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION.</p>
<p>Calcium intake should be adequate.  Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary.</p>
<p>X-rays of the bones should be taken every month until condition is corrected and stabilized.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules of 1.25 mg (50,000 IU vitamin D) of ergocalciferol, USP are green and oval shaped, imprinted with a circled W and "D 92" on one side and plain on the other.</p>
<p>HDPE plastic bottles of 100 capsules (NDC 0024-0393-10).</p>
<p>Store 25°C (77 F); excursions permitted between 15°  – 30°C (59° – 86°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY<br></p>
<p>Revised May 2012</p>
<p>© 2012 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1.25 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC</span> 0024-0393-10<br><span class="Bold">100 capsules</span></p>
<p><span class="Bold">Drisdol</span><span class="Sup">®</span><br>ergocalciferol,<br>1.25 mg (50,000 IU vitamin D)</p>
<p>Store at 25° C (77° F); excursions permitted<br>between 15° - 30° C (59° - 86°F)<br>[see USP Controlled Room Temperature].</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d501431-82d3-4f8e-94c4-5eabcefc00ad&amp;name=drisdol-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DRISDOL 		
					</strong><br><span class="contentTableReg">ergocalciferol capsule, liquid filled</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-0393</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ergocalciferol</strong> (Ergocalciferol) </td>
<td class="formItem">Ergocalciferol</td>
<td class="formItem">1.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow No. 5</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Soybean Oil</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (oval shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;D;92</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-0393-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA003444</td>
<td class="formItem">11/11/1974</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, LLC</td>
<td class="formItem"></td>
<td class="formItem">051762268</td>
<td class="formItem">MANUFACTURE(0024-0393), ANALYSIS(0024-0393)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S. LLC</td>
<td class="formItem"></td>
<td class="formItem">011330557</td>
<td class="formItem">LABEL(0024-0393), PACK(0024-0393)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e9562081-3217-454f-bb4c-b063baa3e35e</div>
<div>Set id: 0d501431-82d3-4f8e-94c4-5eabcefc00ad</div>
<div>Version: 5</div>
<div>Effective Time: 20120615</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
